Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Opinion
Video
Clinical Data Supporting Pneumococcal Vaccination
Author(s):
Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
What is the key data that led to the FDA-approvals of PCV15, PCV20, and PCV21?
How do the polysaccharide and conjugate pneumococcal vaccines differ in terms of immune response and durability?
- Can you discuss the potential long-term benefits of using conjugate vaccines over polysaccharide vaccines in adult populations and vice versa?
Related Videos
Related Content
